SpectraScience said today it acquired the assets of optical imaging system company Oncoscope for an undisclosed amount.
Durham, N.C.-based Oncoscope developed a proprietary optical imaging system designed for the minimally invasive detection of pre-cancerous epithelial tissues using scattered white light, with a target indication for Barrett’s Esophagus.
“The Oncoscope technology is the perfect complement to ours. SpectraScience’s Laser Induced Fluorescence Spectroscopy measures concentration of specific biomarkers in epithelial tissues. The strength of Oncoscope’s technology is its focus on enlarged cell nuclei, an early marker of pre-cancers and cancers. Both technologies arrive at the same conclusion by measuring different indicators. Having two complementary technologies allows us to address multiple types of cancers including both esophageal and colon cancers. Oncoscope’s focus on a diagnostic for Barrett’s Esophagus will shorten the development time for a commercial product to address this indication. With a solution for diagnosis of cancer in the upper GI as well as the lower GI, we will be able to more efficiently utilize our manufacturing capabilities and leverage the sales channel to Gastroenterologists,” SpectraScience CEO Michael Oliver said in prepared remarks.
SpectraScience, based in San Diego, Calif., designs, develops, manufactures and markets spectrophotometry systems designed to determine whether tissue is pre-cancerous or cancerous without removing tissue samples.
The company said its devices have won FDA approval in the U.S. and CE Mark approval in the European Union.